We showed that LTBP3 and SNED1, identified by proteomics in our study as differentially expressed between poorly and highly metastatic mammary tumors, correlate at the transcript level with clinical outcome in a cohort of ER−/PR− breast cancer patient. The gene discussed is LTBP3; the disease is breast carcinoma.